#int230 - Twitter Hashtag

10 months ago

$INTS Study IT-01 first author Jacob S. Thomas, M.D., highlights the #INT230-6’s dual potential to target tumors and activate the immune system. Phase 1/2 data show promising efficacy and favorable safety in advanced #metastaticcancers. Full study: https://t.co/OCG1TEDSeG

IntensityInc's tweet photo. $INTS Study IT-01 first author Jacob S. Thomas, M.D., highlights the #INT230-6’s dual potential to target tumors and activate the immune system.

Phase 1/2 data show promising efficacy and favorable safety in advanced #metastaticcancers.

Full study: https://t.co/OCG1TEDSeG https://t.co/L296Jicx4v

3

23

5

0

2K

Intensity Therapeutics

@IntensityInc

10 months ago

Immunohistochemistry (IHC) results following two #INT230-6 doses in the Phase 1/2 study show T-cell infiltration in a sarcoma patient’s tumor compared to the pre-dose biopsy. Seen in 13/14 matched pair biopsies, supporting proof-of-concept for immune activation in tumors. Read the full study: https://t.co/b1z5WL26Iv $INTS #eBioMedicine

3

24

4

2

2K

Oncology Tube

@oncologytube

almost 5 years ago

Podcast - Data from Ongoing Phase 1/2 Study Matthew A. Ingham, MD @ColumbiaPS @ColumbiaMed #CTOS21 #INT230-6 #MetastaticSarcomas #Cancer #Research Link to Audio: https://t.co/qrBz0yhjK9

oncologytube's tweet photo. Podcast - Data from Ongoing Phase 1/2 Study Matthew A. Ingham, MD @ColumbiaPS @ColumbiaMed #CTOS21 #INT230-6 #MetastaticSarcomas #Cancer #Research

Link to Audio:
https://t.co/qrBz0yhjK9 https://t.co/iJbIqBGObB

0

1

0

Oncology Tube

@oncologytube

almost 5 years ago

Data from Ongoing Phase 1/2 Study Matthew A. Ingham, MD @ColumbiaPS @ColumbiaMed #CTOS21 #INT230-6 #MetastaticSarcomas #Cancer #Research https://t.co/ccEFlkPhPD

oncologytube's tweet photo. Data from Ongoing Phase 1/2 Study Matthew A. Ingham, MD @ColumbiaPS @ColumbiaMed #CTOS21 #INT230-6 #MetastaticSarcomas #Cancer #Research

https://t.co/ccEFlkPhPD https://t.co/pnwO4inBYQ

0

1

0

Top Tweets for #int230

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users